ライフサイエンスコーパス: tobacco use

1 dyslipidemia, gout, alcohol dependence, and tobacco use).

2 e, nonoropharyngeal primaries, or history of tobacco use).

3 bacco use, and 3.6% (95% CI 2.3-5.2) for any tobacco use.

4 ovascular risk factors, including especially tobacco use.

5 re paradigm that may better model adolescent tobacco use.

6 some regions for years of cocaine and daily tobacco use.

7 systemic inflammation, pericardial fat, and tobacco use.

8 than currently agreed should be adopted for tobacco use.

9 early age of initiation for both alcohol and tobacco use.

10 gets for all three of these measures and for tobacco use.

11 oth toxicants and carcinogens resulting from tobacco use.

12 , in many cases cannabis use develops before tobacco use.

13 h-burden countries for both tuberculosis and tobacco use.

14 l, high-density lipoprotein cholesterol, and tobacco use.

15 forts to reduce morbidity and mortality from tobacco use.

16 drawal may have a critical role in promoting tobacco use.

17 ving diet, increasing activity, and reducing tobacco use.

18 bits, increase physical activity, and reduce tobacco use.

19 n other physiological effects of smoking and tobacco use.

20 a diagnosis of bladder cancer on patterns of tobacco use.

21 or lung cancer in patients with a history of tobacco use.

22 de aflatoxin exposure, and heavy alcohol and tobacco use.

23 r offspring disinhibited behavior, including tobacco use.

24 ol can substantially reduce the frequency of tobacco use.

25 the effect of parental smoking on offspring tobacco use.

26 three subjective response factors to initial tobacco use.

27 ine interactions with other antioxidants and tobacco use.

28 S cancer survivors about diet, exercise, and tobacco use.

29 tes, hypercholesterolemia, hypertension, and tobacco use.

30 male sex, white race, abdominal obesity, and tobacco use.

31 s tobacco use, and 27.1% (22.8-31.7) for any tobacco use.

32 t class analysis indicated 5 classes of poly-tobacco use.

33 increased age, prior radiation therapy, and tobacco use.

34 re, both forms of disease are exacerbated by tobacco use.

35 ntation of evidence-based measures to reduce tobacco use.

36 bidities, physical activity, and alcohol and tobacco use.

37 n phenotypes, including hypercoagulation and tobacco use.

38 arkinson's disease and a person's history of tobacco use.

39 106 never exposed, matched for age, sex, and tobacco use.

40 ables after adjusting for sex, diabetes, and tobacco use.

41 yzing the impact of pre transplant recipient tobacco use.

42 of negative events increases with increasing tobacco use.

43 guard future generations from the ravages of tobacco use.

44 nt effective public health policies limiting tobacco use.

45 us cerebrovascular disease) + 0.352 x (prior tobacco use) + 0.376 x (number of devices >2) + 0.016 x

46 cytomegalovirus positivity (1.16, P=0.003), tobacco use (1.16, P=0.02), tacrolimus use at discharge

47 (1.90 [1.38-2.62]; p<0.0001), and smokeless tobacco use (1.32 [1.03-1.69]; p=0.030) than in HIV-nega

48 than 50 years [5.19, (3.05-8.29)]; previous tobacco use [1.40 (1.18-1.66)]; and complicated initial

49 or biliary parasitic disease; however, heavy tobacco use (27%) and diabetes mellitus (16.4%) were par

50 ; lipid disorders, 12%-21%; diabetes, 4%-7%; tobacco use, 5%-16%; and obesity, 4%-9%).

51 ronary artery disease (51%), diabetes (58%), tobacco use (52%), and chronic renal insufficiency (39%)

52 with older age, cytotoxic chemotherapy, and tobacco use; 75% of survivors had symptomatic improvemen

53 A more ambitious target on tobacco use (a 50% reduction) will almost reach the targ

54 persistent opioid use included preoperative tobacco use (adjusted odds ratio [aOR], 1.35; 95% CI, 1.

55 that clinicians ask all pregnant women about tobacco use, advise them to stop using tobacco, and prov

56 ommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco, and prov

57 gestational weight gain, high underlying BP, tobacco use, alcohol consumption, and sedentary lifestyl

58 hnicity, body mass index, physical activity, tobacco use, alcohol consumption, formal education, clin

59 lmonary disease and coronary artery disease, tobacco use, alcohol use, and body mass index were also

60 ultiple measures of socioeconomic status and tobacco use, alcohol use, diet, and physical activity.

61 Pooled prevalence estimates of current tobacco use, alcohol use, low fruit and vegetable intake

62 nd includes assessment of family history and tobacco use along with measurement of body mass index an

63 ing was associated with an increased risk of tobacco use among adolescent offspring.

64 We assessed the prevalence of tobacco use among people living with HIV in LMICs.

65 er, very little is known about the extent of tobacco use among people living with HIV in low-income a

66 Tobacco use among people living with HIV results in exce

67 y, and the potential to create a new form of tobacco use among those no longer interested in taking u

68 rent tobacco use (smoked, smokeless, and any tobacco use) among 6729 HIV-positive men from 27 LMICs (

69 nd other risk factors (eg, viral infections, tobacco use) among lymphoma subtypes contribute to the p

70 ymptoms were significant (P < 0.001) for all tobacco use and abstinence symptoms and for responses to

71 ates of Pittsburgh subjects' self-reports of tobacco use and abstinence symptoms were significant (P

72 the potential ENDS have to alter patterns of tobacco use and affect the health of the public; however

73 Although the most important risk factors are tobacco use and alcohol consumption, the disease is also

74 treatments necessary to dramatically reduce tobacco use and attendant disease.

75 e to use or problem use, as were alcohol and tobacco use and disorders, major depression, and schizot

76 tand the cancer risks of exclusive smokeless tobacco use and dual use of smokeless tobacco with other

77 Prevention and management of tobacco use and exposure to second-hand smoke in pregnan

78 arable prevalence data for patterns of adult tobacco use and factors influencing use are absent for m

79 Tobacco use and greater number of lifetime sexual partne

80 1.42, 3.17) higher odds of reporting current tobacco use and having any alcohol in the past year than

81 Previous studies on smokeless tobacco use and head and neck cancer (HNC) have found in

82 onally representative, longitudinal study of tobacco use and health in the United States.

83 tween 2003 and 2014 from 28 LMICs where both tobacco use and HIV test data were made publicly availab

84 er of lifetime oral sexual partners, current tobacco use and immunosuppression.

85 We used longitudinal data on tobacco use and incident tooth loss in 43,112 male healt

86 by the reversal of socioeconomic gradients; tobacco use and low fruit and vegetable intake have beco

87 l groups; and was partially accounted for by tobacco use and mean arterial pressure.

88 They also had increased tobacco use and more comorbidities.

89 proportional hazards models controlling for tobacco use and other potential confounders, no associat

90 ontribute to the inverse correlation between tobacco use and Parkinson's disease.

91 phic characteristics, lifestyle (alcohol and tobacco use and physical activity), and medication, were

92 ncluded studies presented clear patterns for tobacco use and physical activity, heterogeneity between

93 insomnia, asthma, rhinitis, weight, height, tobacco use and physical activity.

94 ccelerated by gerontogenic behaviors such as tobacco use and physical inactivity, and is also influen

95 Goal 3, setting a global target of reducing tobacco use and premature mortality from non-communicabl

96 The possibility of a causal link between tobacco use and psychosis merits further examination.

97 mprove health behaviors (for example, reduce tobacco use and sedentary behavior and improve diet) of

98 20 years of age were queried regarding their tobacco use and serum cotinine was measured.

99 a diagnosis of bladder cancer on patterns of tobacco use and smoking cessation among patients with in

100 iovascular risk factors, as well as reducing tobacco use and substance abuse, should be leading prior

101 se correlation between a person's history of tobacco use and susceptibility to developing Parkinson's

102 influence lung cancer risk independently of tobacco use and that these diseases are important for as

103 munication to prevent, reduce, and eliminate tobacco use and to guide health policies and clinical pr

104 screening and receipt of an intervention for tobacco use and unhealthy alcohol use as candidate perfo

105 king current perceptions of service members' tobacco use and unmasking the forces perpetuating those

106 obacco smoking, 3.4% (1.8-5.6) for smokeless tobacco use, and 27.1% (22.8-31.7) for any tobacco use.

107 obacco smoking, 2.1% (1.1-3.4) for smokeless tobacco use, and 3.6% (95% CI 2.3-5.2) for any tobacco u

108 alence ratios for tobacco smoking, smokeless tobacco use, and any tobacco use separately for males an

109 other vegetables, age, sex, race/ethnicity, tobacco use, and caffeine.

110 f traditional risk factors (such as obesity, tobacco use, and genetic predisposition) and HIV-specifi

111 ms, hiatal hernia, elevated body mass index, tobacco use, and intra-abdominal distribution of fat) to

112 difying risk factors such as alcohol intake, tobacco use, and lack of exercise.

113 s, obesity, dyslipidemia, drug dependence or tobacco use, and renal disease.

114 ociated with early initiation of alcohol and tobacco use, and rs6495309 has been associated with nico

115 ace/ethnicity, education, employment status, tobacco use, and scanner technology.

116 ng for sex, race, education, income, region, tobacco use, and select chronic medical conditions (0-1

117 perative group clinical trials do not assess tobacco use, and there is no observable trend in improve

118 risk factors associated with salt intake and tobacco use, and to model the effects on chronic disease

119 s and globally, to monitor tobacco products, tobacco use, and tobacco-related disease, including toba

120 residence, applicator license type, chewing tobacco use, and total lifetime days of all pesticide us

121 Smokeless tobacco use appears to be associated with HNC, especiall

122 her pre-onset cannabis use, alcohol use, and tobacco use are associated with an earlier age at onset

123 Rates of dual and poly-tobacco use are high among trainees, and while these gro

124 prevent initiation and promote cessation of tobacco use are needed to reduce associated morbidity an

125 ng suboptimal diet, physical inactivity, and tobacco use, are leading causes of preventable diseases

126 Tobacco use as a risk factor and the effect of changes i

127 similar in magnitude to that associated with tobacco use, as compared with no use (hazard ratio, 1.54

128 Cooperative Group Program were evaluated for tobacco use assessment at enrollment and follow-up by us

129 The purpose of this study was to evaluate tobacco use assessment in patients enrolled onto activel

130 al laboratories as well as for point-of-care tobacco use assessment.

131 ials reviewed, 45 (29%) assessed any form of tobacco use at enrollment, but only 34 (21.9%) assessed

132 -demographic factors, CD4 count, alcohol and tobacco use, baseline WHO stage 4 disease, social suppor

133 As the risks of tobacco use become recognized and smoking becomes stigma

134 Respondents completed a survey on history of tobacco use, beliefs regarding bladder cancer risk facto

135 Stopping tobacco use benefits virtually every smoker.

136 ied according to centre, performance status, tobacco use, best response to previous EGFR tyrosine-kin

137 ared weighted point estimates and 95% CIs of tobacco use between these 14 countries and with data fro

138 nts also reveal hidden relationships between tobacco use, body mass index, and blood pressure.

139 Betel chewing was associated with tobacco use but not with cannabis or alcohol.

140 are effective measures to reduce alcohol and tobacco use, but are not available to target illicit dru

141 This study hypothesized that tobacco use by PAD patients would be associated with hig

142 Methamphetamine and/or tobacco use by pregnant women remains prevalent.

143 ints were biomarker-calibrated self-reported tobacco use by the mother at late pregnancy, birthweight

144 vey (GYTS), we aimed to assess the effect of tobacco use by young people on global mortality.

145 ditions, birth defects, reproductive health, tobacco use, cancer, violence, legal debate, and terrori

146 health at age 38, even after controlling for tobacco use, childhood health, and childhood socioeconom

147 ssued a separate recommendation statement on tobacco use counseling in adults and pregnant women.

148 archers should use caution when interpreting tobacco use data obtained from check-all-that-apply form

149 rable changes in lifestyle such as increased tobacco use, decreased physical activity, and consumptio

150 Linear regression adjusted for income, tobacco use, dental insurance, and previous radiation an

151 al addictive component that drives continued tobacco use despite users' knowledge of the harmful cons

152 , if risk factor targets for blood pressure, tobacco use, diabetes mellitus, and obesity are achieved

153 ce/ethnicity, and income level), alcohol and tobacco use, diabetes mellitus, and past periodontal tre

154 Tobacco use did not change significantly, but the 10-yea

155 and caffeine withdrawal syndromes, aligning tobacco use disorder criteria with other substance use d

156 Tobacco use disorder is associated with dysregulated neu

157 ission and enhancing IC during the course of tobacco use disorder treatment.

158 ase; 6) hyperlipidemia; 7) alcohol abuse; 8) tobacco use disorder; and 9) random effect of geographic

159 tudy of Nicotine Dependence (ascertained for tobacco use disorder; n = 918 cases; 988 control subject

160 nly seven trials (4.5%) assessed any form of tobacco use during follow-up.

161 nicotine replacement therapy, and smokeless tobacco use during pregnancy are associated with cogniti

162 fluid balance, obesity, hypoxemia, acidosis, tobacco use, emergent hematoma evacuation, and vasopress

163 o more effectively prevent the initiation of tobacco use, especially for youth and young adults.

164 which might include behaviors such as lesser tobacco use, greater physical activity, and/or enhanced

165 Tumors from patients with a history of tobacco use had more mutations than did tumors from pati

166 art failure, peripheral arterial disease, or tobacco use had the largest predicted differences in sur

167 Substantial evidence suggests that tobacco use has adverse effects on cancer treatment outc

168 e 50 years who have no history of alcohol or tobacco use has been recorded over the past decade.

169 Tobacco use has fallen in countries that are members of

170 ent outcomes; however, routine assessment of tobacco use has not been fully incorporated into standar

171 To date, most genetic association studies of tobacco use have been conducted in European American sub

172 ets for reducing systolic blood pressure and tobacco use have more substantial effects on future scen

173 t were relevant to primary care and reported tobacco use, health outcomes, or harms were included.

174 l concentrated among patients with diabetes, tobacco use, heart failure, or peripheral arterial disea

175 s for SCD: older age, African-American race, tobacco use, higher pulse, higher waist-to-hip ratio, el

176 icantly associated with STAT3 activation and tobacco use history in non-small cell lung cancer (NSCLC

177 ients with diabetes (HR, 0.88), a history of tobacco use (HR, 0.82), heart failure (HR, 0.84), and pe

178 RNA (HR, 1.19 [95% CI, 1.02-1.38], P = .02), tobacco use (HR, 1.37 [95% CI, 1.02-1.85], P = .04), CD4

179 Among patients with ERAF, only current tobacco use (HR, 3.84; 95% CI, 1.82-8.11; P<0.001) was a

180 Age, sex, tobacco use, hypercholesterolemia, hypertension, and typ

181 antly to the global burden of CVD, including tobacco use, hypertension, and secondary prevention for

182 .002) after adjusting for age group and past tobacco use in a multivariable model.

183 s on the rates of initiation or cessation of tobacco use in children and adolescents and on health ou

184 sociated with an increased risk of offspring tobacco use in later life.

185 otential for creating an alternative form of tobacco use in light of declining cigarette sales and so

186 acco industry's future depends on increasing tobacco use in low-income and middle-income countries (L

187 ically associated with the long-term risk of tobacco use in offspring.

188 use, and tobacco-related disease, including tobacco use in oncology clinical trials.

189 Tobacco use in PAD is associated with substantial increa

190 INTERPRETATION: The high prevalence of tobacco use in people living with HIV in LMICs mandates

191 Pooled prevalence of any tobacco use in pregnant women in LMICs was 2.6% (95% CI

192 Overall, tobacco use in pregnant women in LMICs was low; however

193 We assessed the magnitude of tobacco use in pregnant women in LMICs.

194 However, the extent of tobacco use in pregnant women in low-income and middle-i

195 The pooled prevalence of current smokeless tobacco use in pregnant women was lowest in the European

196 nction as a potential mechanism for elevated tobacco use in schizophrenia and also identify activatio

197 r brief counseling, to prevent initiation of tobacco use in school-aged children and adolescents.

198 e approaches to reduce the growing burden of tobacco use in the developing world.

199 gress toward lowering the prevalence rate of tobacco use in the U.S. and lowering the rate of tobacco

200 etween maternal smoking during pregnancy and tobacco use in young adulthood, an association that was

201 ctors associated with poly-tobacco (vs. mono-tobacco) use included lower confidence to remain tobacco

202 ities for significantly reducing the toll of tobacco use, including: (1) the need for novel, nonlinea

203 ny cancer cases in India are associated with tobacco use, infections, and other avoidable causes.

204 fair-quality) that were designed to prevent tobacco use initiation or promote cessation (or both) an

205 Tobacco use is a leading cause of preventable death worl

206 Tobacco use is a leading contributor to disability and d

207 Tobacco use is a leading preventable risk factor for man

208 ctive, one beneficial consequence of chronic tobacco use is a reduced risk for Parkinson's disease.

209 Tobacco use is an established risk factor for the develo

210 Tobacco use is an important preventable cause of periphe

211 Tobacco use is an underappreciated risk for Barrett's es

212 Tobacco use is associated with 5 million deaths per year

213 A number of studies agree that tobacco use is associated with an increased rate of aneu

214 First, that daily tobacco use is associated with an increased risk of psyc

215 Daily tobacco use is associated with increased risk of psychos

216 The evidence against tobacco use is clear, incontrovertible, and convincing;

217 Tobacco use is predicted to result in over 1 billion dea

218 vernments can create an environment in which tobacco use is reduced and citizens maintain good levels

219 Tobacco use is responsible for a large proportion of the

220 Tobacco use is the leading cause of preventable death in

221 Tobacco use is the leading preventable cause of death wo

222 Tobacco use is the leading risk factor for PAD incidence

223 Tobacco use is the single greatest cause of premature an

224 tional individual level risk factors (mainly tobacco use, lipids, and elevated blood pressure) and so

225 e that health professionals have in reducing tobacco use, many have a smoking habit themselves.

226 Furthermore, antipsychotics and tobacco use may increase CB1R availability in this popul

227 Validity estimates of some tobacco use measures were significant for Oregon subject

228 socioeconomic, mental health, and drug- and tobacco-use measures were used to estimate mortality ris

229 that disparities in hypertension related to tobacco use might be masked by differences in body mass

230 ionally representative sources that measured tobacco use (n = 2102 country-years of data) were system

231 The health effects of smokeless tobacco use need further documentation.

232 rovides evidence-based policies for reducing tobacco use, no global policy exists for the control of

233 he benefits of population-wide reductions in tobacco use, obesity, and cholesterol levels.

234 The prevalence of tobacco use, obesity, and hypertension, was 7.8%, 2.4%,

235 x (BMI), hypertension, diabetes, alcohol and tobacco use, ocular conditions (including blindness, cat

236 n integral role in affecting the patterns of tobacco use of those newly diagnosed.

237 accurately understand the precise effect of tobacco use on cancer treatment outcomes.

238 f coronary artery disease, but the impact of tobacco use on cardiac structure and function in the gen

239 t the effect of comorbid methamphetamine and tobacco use on human fetal brain development.

240 vealed no significant effects of cannabis or tobacco use on risk of onset, analysis of change in freq

241 alth (nutrition, environment/occupation, and tobacco use) on day 2.

242 analysis of PHS with adjustment for age and tobacco use only, completely edentulous elderly adults (

243 ression modeling with adjustment for age and tobacco use only; and 2) logistic regression modeling wi

244 r point, 1.92; 95% CI, 1.55-2.37; P < .001), tobacco use (OR, 3.64; 95% CI, 1.36-9.73; P = .01), ence

245 95% confidence interval [95% CI]=1.25-2.61), tobacco use (OR=1.41, 95% CI=1.02-1.94), obesity (OR=1.9

246 nt with offspring's smoking, age at onset of tobacco use, or changes in use between 2006 and 2010.

247 dence intervals for the associations between tobacco use, oral health indicators, and PD risk.

248 e likely to report initiation of combustible tobacco use over the next year.

249 , more years on dialysis before waitlisting, tobacco use, panel-reactive antibody greater than 0, pub

250 outine component of the standard of care for tobacco-using patients.

251 nmental factors, such as risk perceptions of tobacco use, peer use, and tobacco-company influences.

252 from a short list of risk factors--including tobacco use, poor diet and physical inactivity (both str

253 In conclusion, the genetics of alcohol and tobacco use potentially has broader implications on phys

254 able analysis including age, gender, current tobacco use, prehospital aspirin use, race, and Acute Ph

255 pressure, heart rate, change in heart rate, tobacco use, presence of diabetes mellitus, alcohol use,

256 The difference in smokeless tobacco use prevalence between HIV-positive and HIV-nega

257 mputer-assisted interviews with the Lifetime Tobacco Use Questionnaire from 2005 through 2008.

258 e to preventive practices from 1999 to 2010, tobacco use remained high, and almost half of U.S. adult

259 Combustible tobacco use remains the number-one preventable cause of

260 Tobacco use remains the single most common modifiable ca

261 higher prevalence in HIV-positive men of any tobacco use (risk ratio [RR] 1.41 [95% CI 1.26-1.57]) an

262 hypertension, diabetes, hyperlipidemia, and tobacco use, risk differences comparing participants wit

263 gher prevalence in HIV-positive women of any tobacco use (RR 1.36 [95% CI 1.10-1.69]; p=0.0050), toba

264 formation on several risk factors, including tobacco use, secondhand exposure to cigarette smoke, obe

265 acco smoking, smokeless tobacco use, and any tobacco use separately for males and females to study di

266 Prevalence of current tobacco use (smoked and smokeless) was estimated for eve

267 regional, and overall prevalence of current tobacco use (smoked, smokeless, and any tobacco use) amo

268 ression analyses, adjusted for education and tobacco use (snuff use in the smoking analysis and smoki

269 participants without a history of alcohol or tobacco use, suggesting that observed associations with

270 een effects of arsenic exposure and those of tobacco use, sun exposure, and pesticide and fertilizer

271 General Lifestyle Survey and the 2006-07 US Tobacco Use Supplement to the Current Population Survey.

272 intentions to smoke are predictive of later tobacco use, survivors as young as 10 years of age who w

273 We questioned students about current tobacco use, susceptibility to smoking among non-smokers

274 Model 1 used age, sex, tobacco use, systolic blood pressure, antihypertensive m

275 ch, commensurate with the enormous toll that tobacco use takes on human health, to provide the scient

276 Current tobacco use, the apolipoprotein E epsilon4 genotype, and

277 we examined the distribution of duration of tobacco use, the OR for p16(INK4A) homozygous deletion w

278 L-C levels, age, hypertension, diabetes, and tobacco use, there was a significant inverse association

279 rictions, augmenting access to treatment for tobacco use through insurance coverage and telephone hel

280 ourth priority is a UN high-level meeting on tobacco use to galvanise global action towards the 2040

281 amples is of great importance to testing for tobacco use, tobacco cessation treatment, and studies on

282 atus, histology, tumor location, hemoglobin, tobacco use, treatment arm (AM v no AM) and QOL scores (

283 Behavioural risk factors, including tobacco use, unhealthy diets, and physical inactivity ar

284 oeconomic status and harmful use of alcohol, tobacco use, unhealthy diets, and physical inactivity wi

285 Reductions in tobacco use, uptake of preventive measures, adoption of

286 We found that tobacco use was associated with a lower risk of PD in ma

287 cated that progression to daily cannabis and tobacco use was associated with an increased risk of ons

288 Unlike cannabis use, tobacco use was associated with worse lung function, sys

289 the patient's oral health after cessation of tobacco use was dramatic and reinforces the belief that

290 ion, diabetes, obesity, lipid disorders, and tobacco use were among the most common coexisting condit

291 ger lesion size, nonupper lobe location, and tobacco use were associated with increased diagnostic yi

292 Marijuana and tobacco use were each independently associated with high

293 en, hospital stays in the past 6 months, and tobacco use were included, the adjusted HR was 0.73 (95%

294 A high body mass index and current tobacco use were the only independent risk factors for d

295 cotine and cotinine in hair as biomarkers of tobacco use where in the past the detection of cotinine

296 nary function and other covariates including tobacco use, which was analyzed in parallel as a positiv

297 been described, including chronic heartburn, tobacco use, white race, and obesity.

298 older, peripheral artery disease, diabetes, tobacco use, white race, stroke, atrial fibrillation, co

299 participants (22.7%) subsequently initiated tobacco use within 5 years of study enrollment.

300 Prohibiting tobacco use would be entirely consistent with other mili